PreS1 Mutations Alter the Large HBsAg Antigenicity of a Hepatitis B Virus Strain Isolated in Bangladesh.
PMID: 31952213
2020
International journal of molecular sciences
Conclusion: preS1 C2964A, RT domain I91L, and small HBsAg N3S mutations were found, all of which have clinical
Result: However, some mutations (H9Y, N13H, I91L, I269L, and V278I) were found in the RT domain that are not associated with drug resistance, according to Geno2pheno:hbv.
Result: Only one putative NA-resistant mutation, I91L, was found, and no primary, secondary, pre-treatment, or drug-resistant mutations were observed in the RT domain of Pol.
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Method: Our literature based pooled incidence data showed that several putative or pretreatment mutations, including rtI91L, mutations in 6 positions of A-B interdomain (rtY124H, rtY126C/R/H, rtT128I/N, rtD134E/N, rtN139D/E/H/K/Q and rtW153Q/R/E), rtF221Y and rtI224V, were encountered with high frequency from t
Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B.
Introduction: Recently, HBVrt domain mutations which have been reported in the literature as supposed drug resistant mutations but are not verified experimentally were classified as putative NA resistant (NAr) mutations (such as S53N, T54N, L82M, V84M, S85A, I91L, Y126C, T128I, T128N, N139D, W153Q, F166L).
Result: All the isolates having rt
Table: I91L
Discussion: Our study showed that rtI91L was favored in HBV/C and HBV/D.
Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naive chronic HBV patients.